Trauma

Resuscitation

EMS

Airway

Thoractomy

REBOA

Damage Control

Neuro

TBI

SCI

Head/neck

Thoracic

Damage Control Thoracic Surgery

Cardiac injury

Rib fractures

Abdominal/Gastrointestinal

Hemorrhage

  • PROPPR Trial: Among patients with severe trauma and major bleeding, early administration of plasma, platelets, and red blood cells in a 1:1:1 ratio compared with a 1:1:2 ratio did not result in significant differences in mortality at 24 hours or at 30 days. However, more patients in the 1:1:1 group achieved hemostasis and fewer experienced death due to exsanguination by 24 hours. Even though there was an increased use of plasma and platelets transfused in the 1:1:1 group, no other safety differences were identified between the 2 groups.
  • CRASH-2 Trial: Tranexamic acid safely reduced the risk of death in bleeding trauma patients in this study. On the basis of these results, tranexamic acid should be considered for use in bleeding trauma patients.
  • CRYOSTAT-2 Trial: Among patients with trauma and bleeding who required activation of a major hemorrhage protocol, the addition of early and empirical high-dose cryoprecipitate to standard care did not improve all cause 28-day mortality.
  • Trauma-induced coagulopathy: What you need to know

Hematology

VTE

Vascular Trauma

Aortic Injury

Angioembolization

Vascular Injury

BCVI

Orthopedics

Infectious Disease

Pediatrics

Obstetrics